Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Cidara To Take Rezafungin Into Phase III In Two Severe Infection Indications

19 Mar 2018

• By Joseph Haas

Infectious disease

Related Content

Cidara CEO Stein brings Trius gang, biotech vets together

01 Jul 2014

BIO Notebook, Day 3: Lilly Expands R&D Site, Sigilon Raises Cash And CytomX Talks Deal Strategy

22 Jun 2017

Pipeline Watch: Phase III Read-Outs For Ozanimod, Olaparib And Sapacitabine

27 Feb 2017

Related Companies

Cidara Therapeutics, Inc.

Merck & Co., Inc.

Astellas Pharma, Inc.

Trius Therapeutics, Inc.

Additional Topics

Research & Development Clinical Trials Companies Drug Approval Standards Rare Diseases Infectious Diseases BioPharmaceutical

More from R&D

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.